	US 12,455,280 B2
	Ligand discovery and gene delivery via retroviral surface display
Michael Birnbaum, Arlington, MA (US); and Connor Dobson, Somerville, MA (US)
Assigned to Massachusetts Institute of Technology, Cambridge, MA (US)
Filed by Massachusetts Institute of Technology, Cambridge, MA (US)
Filed on Jan. 9, 2025, as Appl. No. 19/014,949.
Application 19/014,949 is a continuation of application No. 18/458,657, filed on Aug. 30, 2023, granted, now 12,222,347.
Application 18/458,657 is a continuation of application No. 16/826,665, filed on Mar. 23, 2020, granted, now 12,061,187.
Claims priority of provisional application 62/851,889, filed on May 23, 2019.
Prior Publication US 2025/0147007 A1, May 8, 2025
This patent is subject to a terminal disclaimer.
Int. Cl. G01N 33/50 (2006.01); C07K 14/005 (2006.01); C07K 14/47 (2006.01); C07K 14/54 (2006.01); C07K 14/705 (2006.01); C07K 14/74 (2006.01); C07K 16/28 (2006.01); C12N 15/86 (2006.01)

CPC G01N 33/505 (2013.01) [C07K 14/005 (2013.01); C07K 14/4748 (2013.01); C07K 14/5437 (2013.01); C07K 14/70532 (2013.01); C07K 14/70539 (2013.01); C07K 16/2803 (2013.01); C12N 15/86 (2013.01); C07K 2317/622 (2013.01); C07K 2319/02 (2013.01); C07K 2319/035 (2013.01); C07K 2319/60 (2013.01); C12N 2740/15045 (2013.01)]

26 Claims

1. A lentivirus comprising:

(a) a nucleic acid;

(b) a viral envelope comprising

(i) a vesicular stomatitis virus (VSV)-G envelope protein comprising an amino acid sequence at least 95% identical to SEQ ID NO: 13, wherein the VSV-G envelope protein comprises an amino acid substitution at position 47 (lysine, K) and/or position 354 (arginine, R), wherein the amino acid substitution(s) diminish the native viral tropism of the VSV-G envelope protein compared to the non-mutated VSV-G envelope protein; and

(ii) a non-viral membrane-bound protein comprising a transmembrane-domain and an extracellular targeting domain that binds to a ligand expressed on the surface of a T cell or a B cell.